These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24685746)

  • 1. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature.
    Ripamonti D; Benatti SV; Di Filippo E; Ravasio V; Rizzi M
    AIDS; 2014 Apr; 28(7):1077-9. PubMed ID: 24685746
    [No Abstract]   [Full Text] [Related]  

  • 2. Raltegravir-induced DRESS syndrome.
    Loulergue P; Mir O
    Scand J Infect Dis; 2012 Oct; 44(10):802-3. PubMed ID: 22803794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.
    Perry ME; Almaani N; Desai N; Larbalestier N; Fox J; Chilton D
    Int J STD AIDS; 2013 Aug; 24(8):639-42. PubMed ID: 23970584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benchmark for management of drug resistant HIV.
    Pozniak AL; Arribas JR
    Lancet Infect Dis; 2013 Jul; 13(7):561-2. PubMed ID: 23664332
    [No Abstract]   [Full Text] [Related]  

  • 5. Low frequency of skin reactions in a cohort of patients on raltegravir.
    Bonfanti P; Ricci E; Molteni C; De Socio GV; Rusconi S; Vichi F; Penco G; Antinori A; Cordier L; Maggi P; Celesia BM; Grosso C; Quirino T
    J Antimicrob Chemother; 2012 Jul; 67(7):1800-2. PubMed ID: 22441576
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
    Warpakowski A
    MMW Fortschr Med; 2011 May; 153(18):50-1. PubMed ID: 21604599
    [No Abstract]   [Full Text] [Related]  

  • 7. Resolution of autoimmune thrombocytopenia associated with raltegravir use in an HIV-positive patient.
    Gentile I; Bonadies G; Buonomo AR; Minei G; Borrelli F; Foggia M; Chiurazzi F; Borgia G
    Platelets; 2013; 24(7):574-7. PubMed ID: 23130846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study.
    Madeddu G; Menzaghi B; Ricci E; Carenzi L; Martinelli C; di Biagio A; Parruti G; Orofino G; Mura MS; Bonfanti P;
    AIDS; 2012 Nov; 26(18):2412-5. PubMed ID: 23032413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The pillars of modern HIV therapy: effectiveness, tolerance, compatibility].
    MMW Fortschr Med; 2012 May; 154 Suppl 1():40-1. PubMed ID: 22916599
    [No Abstract]   [Full Text] [Related]  

  • 10. Initial results reported on raltegravir once-daily dosing.
    AIDS Patient Care STDS; 2011 Feb; 25(2):123. PubMed ID: 21370546
    [No Abstract]   [Full Text] [Related]  

  • 11. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
    Macías J; Neukam K; Portilla J; Iribarren JA; de Los Santos I; Rivero A; Márquez M; Delgado M; Téllez F; Merino D; Giner L; von Wichmann MA; Pineda JA;
    J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA notifications. FDA grants approval for raltegravir.
    AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
    [No Abstract]   [Full Text] [Related]  

  • 13. Raltegravir as effective as efavirenz in 144-week data.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
    [No Abstract]   [Full Text] [Related]  

  • 14. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
    Monteiro P; Perez I; Pich J; Gatell JM; Martínez E
    J Antimicrob Chemother; 2013 Feb; 68(2):404-8. PubMed ID: 23109185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir-induced nephrolithiasis: a case report.
    Vassallo M; Dunais B; Naqvi A; Garaffo R; Durant J
    AIDS; 2012 Jun; 26(10):1323-4. PubMed ID: 22706013
    [No Abstract]   [Full Text] [Related]  

  • 16. Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.
    Yee BE; Nguyen NH; Lee D
    BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24798353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentations of severe cutaneous drug reactions in HIV-infected Africans.
    Lehloenya RJ; Kgokolo M
    Dermatol Clin; 2014 Apr; 32(2):227-35. PubMed ID: 24680008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir as a trigger for DRESS syndrome?
    Martin C; Payen MC; De Wit S
    Int J STD AIDS; 2018 Sep; 29(10):1036-1038. PubMed ID: 29621952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.